ASH Clinical Practice Guidelines on Amyloidosis
The American Society of Hematology is accepting nominations (including self-nominations) of individuals to serve on a panel that will develop new Clinical Practice Guidelines on Diagnosis of Amyloidosis. Please complete the nomination form with as much detail as possible. This survey is estimated to require 10-15 minutes to complete. ASH kindly asks that you complete this survey by November 25, 2022. Thank you for your interest in clinical guidelines on Amyloidosis.
In 2021, in response to long-standing member interest, ASH initiated an effort to develop evidence-based clinical practice guidelines for hematology that meet the highest standards of development, rigor and trustworthiness. Development of these guidelines, including systematic evidence review, will be supported by a methodology team. With their partnership, ASH will work to convene an initial panel of experts to review evidence and formulate recommendations addressing the initial diagnostic evaluation and workup for amyloidosis in general (both types, AL and ATTR). A second panel covering the treatment of Amyloidosis will follow.
Download ASH’s COI policy to learn more about management of conflicts of interest in the development of Clinical Practice Guidelines by the American Society of Hematology.
ASH continues its long-standing commitment to supporting scientists and clinicians from backgrounds underrepresented in medicine and embraces diverse voices across the patient and health care communities. Learn more about ASH’s commitment to diversity, equity and inclusion in health care.